Abstract:BACKGROUND: Pegylated liposomal doxorubicin (CAELYX®) is a liposomal formulation of doxorubicin sterically stabilized by the grafting of segments of polyethylene glycol (PEG) onto the liposomal surface. Given the demonstrated efficacy of VAD (vincristine and doxorubicin and oral dexamethasone) in Multiple Myeloma (MM) patients and the potential for CAELYX® to extend the duration of bone marrow exposure to therapeutic levels of doxorubicin, a combination regimen of CAELYX®, vincristine, and reduced-dose dexamethasone (DVD) has been actively investigated in MM patients. Studies showed that substituting CAELYX® for doxorubicin in the VAD regimen and reducing the dose of dexamethasone in MM patients improves the safety profile and convenience of the treatment regimen without compromising efficacy. Due to potential differences in metabolism of these patients, safety and efficacy results may vary. Thus, we carried out this study in 82 newly diagnosed MM patients in China, in order to demonstrate the efficacy and safety profiles of DVD. METHODS: Patients (n=82) from 15 sites were recruited in this study. CAELYX® (40mg/m 2 ) was infused intravenously over 60-minutes, administered every 28 days. Vincristine (2.0mg) was administered intravenously on Day 1 of each cycle. Dexamethasone (40 mg) was administered from Day 1- Day 4 of each cycle orally or intravenously. The treatment was repeated every 28 days for 4 cycles. RESULTS: Upon ITT analysis, the overall response rate was approximately 68% (56/82); 11% of the patients achieved complete remission (CR), 40% achieved partial response (PR), 17% achieved minimal response; 15% had stable disease (SD), and 12% o had progressive disease (PD) after the treatment. The cumulative 4-month progression-free survival (PFS) was 88%. The incidence of all the adverse events was 46%. The most common non-hematological toxicities were palmar-plantar erythrodysesthesia (13.4%) and stomatitis (6.1%), respectively. CONCLUSION: Pegylated liposomal doxorubicin, vincristine and reduced dose dexamethasone combination (DVD) regimen is an effective and safe regimen in newly diagnosed multiple myeloma patients in Chinese population.

Clinical Observation on Navelbine Combined with Pirarubicin in Treatment of Multiple Myeloma by Combined Chemotherapy

Clinical Observation of Gemcitabine Combined with Cisplatin As Second- or Third-Line on Patients with Advanced Triple-Negative Breast Cancer

Clinical observation of NVB-contained chemotherapeutic regimen in advanced breast cancer

A Clinical Study of Bortezomib in Combination with Dexamethasone And/or Doxorubibcin for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

An Open-Label Study of Pegylated Liposomal Doxorubicin, Vincristine and Reduced-Dose Dexamethasone Combination Therapy in Newly Diagnosed Multiple Myeloma Patients in Chinese Population.

Evaluation of Efficacy and Toxicity of Gemcitabine in Combination with Vinorelbine in Metastatic Breast Cancer Patients Previously Treated with Anthracyclines and Taxanes

Clinical research of multiple myeloma with Velcade treatment

[Bortezomib-Based Combination Therapy for Newly Diagnosed Multiple Myeloma].

The Clinical Efficacy Observation of VAD Regimen in the Treatment of Newly Diagn Osed Multiple Myeloma

Effect of bortizomib in combination with modified VAD chemotherapy on multiple myelo-ma

The nursing of subcutaneous injection of bortezomib therapy during hemodialysis for multiple myeloma combined with renal failure

Vinorelbine based combination chemotherapy in advanced non-small cell lung cancer

A Single-Center Retrospective Analysis of 100 Consecutive Cases Treated with Lenalidomide/bortezomib/dexamethasone in Newly Diagnosed Multiple Myeloma

Bortezomib Combined with Dexamethasone for Newly Diagnosed Multiple Myeloma

[Efficacy and Toxicity of Vinorelbine (Nvb)-Based Regimens in Patients with Metastatic Triple Negative Breast Cancer (mtnbc) Pretreated with Anthracyclines and Taxanes].

Clinical efficacy of navelbine plus cisplatin in the treatment of advanced non - small cell lung cancer

Treatment and Prognostic Factors for Survival in Newly Diagnosed Multiple Myeloma Patients with Bortezomib and Dexamethasone Regimen: a Single Chinese Center Retrospective Study

Analysis of velcade combined with dexamethasone regimen treating multiple myeloma

Comparison of NP Regimen and TP Regimen in Treatment of Advanced Breast Cancer

[A Cohort Study Comparing the Efficacy and Safety of Bortezomib Plus Dexamethasone Versus Bortezomib, Epirubicin and Dexamethasone in Patients with Multiple Myeloma].

Curative Effect of Mitoxantrone Plus Thalidomide and Dexamethasone on Treatment of Multiple Myeloma